Reconnecting

The current page stays visible while onset.to reconnects in the background.

onset.to

← All weeks

Highlights Aug 24 - Aug 30, 2026

new every Sunday

This week brought clearer evidence on Oregon's regulated psilocybin services, microdosing, cognition, and possible mechanisms, alongside an open-science step for ibogaine. The findings also exposed practical gaps in funding, safety, and translation to care.

  1. 01 Oregon's state-licensed psilocybin program shows strong real-world outcomes as regulators consider fees that could threaten its survival

    Oregon's first peer-reviewed service cohort reports outcomes and adverse reactions as proposed fees threaten provider viability.

    behavioralwire.com · Aug 23, 2026 Psilocybin Clinical
  2. 02 Metaanalyse zu Psychedelika im Microdosing findet bei gesunden Erwachsenen keinen konsistenten unmittelbaren Nutzen

    A 24-study meta-analysis finds no consistent immediate benefit from psychedelic microdosing in healthy adults.

    psychedelia-stiftung.de · Aug 26, 2026 LSD Microdosing
  3. 03 Systematische Übersichtsarbeit zeigt uneinheitliche Auswirkungen von LSD, DMT und Psilocybin auf kognitive und psychologische Funktionen

    A 32-study review finds dose-related acute impairment, mixed longer-term effects, and persistent limits from weak blinding.

    psychedelia-stiftung.de · Aug 24, 2026 LSD Research
  4. 04 University of Miami’s Gift of Its 1994 Ibogaine IND to HHS Advances Open Science While Highlighting Modern Safety and Sourcing Needs

    Miami's 1994 ibogaine IND becomes a public resource, while modern cardiac-safety and sourcing needs remain unresolved.

    maps.org · Aug 25, 2026 Ibogaine Research
  5. 05 Psilocybin reverses depressive-like behaviors and restores hippocampal neuron growth in chronically stressed rats

    In stressed rats, two low psilocybin doses restored hippocampal neuron growth and improved several depression-like behaviors.

    psypost.org · Aug 29, 2026 Psilocybin Research
  6. 06 What is stopping psychedelic therapy in China? Jennifer Docherty on clinicians, family decision-making, and end-of-life care

    Interviews with Hong Kong clinicians show how family authority, stigma, drug controls, and palliative-care gaps may shape access.

    themicrodose.substack.com · Aug 24, 2026 Psilocybin Clinical
  7. 07 The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It

    The 5-MeO-DMT patent landscape shows clinical leadership and intellectual-property control may not belong to the same companies.

    altitude-online.com · Aug 24, 2026 5-MeO-DMT Business